Abstract:Objective To evaluate the effect of high-dose glucocorticoid on adrenal cortex in patients with thyroid associated ophthalmopathy (TAO). Methods A total of 48 patients with active severe TAO were divided into intermittent treatment group (n=24) and maintenance treatment group (n=24) by stratified random method. All patients received intravenous infusion of methylprednisolone 500 mg/d for 3 consecutive days as a course of treatment at intervals of 4 weeks (a total of of six courses). In the maintenance group, the patients were treated with oral prednisone in the interim period; the initial dose was 10 mg/d and the drug was gradually reduced and stopped within four weeks. The function of thyroid gland and the levels of related antibodies were examined before treatment. Clinical activity score (CAS) and NOSPECS level were evaluated, and the ocular condition, including exophthalmos, the thickness of extraocular muscles, double vision and intraocular pressure was assessed before treatment, 4 and 24 weeks after treatment. At the same time, the levels of serum cortisol, adrenocorticotropic hormone (ACTH) and 24-hour urinary cortisol were detected. Results There were no significant differences in the function of thyroid gland or the levels of related antibodies between two groups (all P>0.05). Neither were the effective rate of treatment (83.3% in the intermittent treatment group and 87.5% in the maintenance treatment group) at the end of the treatment and recurrence rate (20.0% in the intermittent treatment group and 19.0% in the maintenance treatment group) 4 to 24 weeks after treatment (P>0.05). CAS score, NOSPECS level, exophthalmos, the thickness of extraocular muscles and intraocular pressure were significantly decreased 4 and 24 weeks after treatment as compared with those before treatment (all P<0.05). And intraocular pressure at the end of 24 weeks after treatment was significantly lower than that at 4 weeks after treatment (all P<0.05). Adrenocortical function was normal before treatment and 4 weeks afer treatment. In the maintenance treatment group, the levels of serum cortisol, adrenocorticotropic hormone (ACTH) and 24-hour urinary cortisol were significantly lower than those before treatment and 24 week after treatment (all P<0.05). The incidence of adverse reaction in the maintenance treatment group was significantly higher than that in the intermittent treatment group (85.7% vs. 30.0%, P<0.05). Conclusions High dose methylprednisolone intermittent therapy is effective for thyroid associated ophthalmopathy. The clinical outcomes are not significantly improved in the patiens with oral prednisone in the interval, but there are more adverse effects and the adrenal function is significantly inhibited.

The Clinical Analysis of Thyroid-Assocaited Ophthalmopathy with Optic Neuropathy

[Clinical Analysis of 339 Cases of Thyroid-Associated Ophthalmopathy].

Thyroid-associated ophthalmopathy: a clinical study of 381 cases]

Clinical Analysis of 106 Cases with Elevated Intraocular Pressure in Thyroid-Associated Ophthalmopathy.

Clinical analysis of l06 cases with intraocular pression in thyroid-assocated ophthalmopathy

[Clinical Analysis of 2 170 Cases of Thyroid-Associated Ophthalmopathy Involving Extraocular Muscles].

Assessment Method of Thyroid Associated Ophthalmopathy and Its Steroid Treatment Process

Clinical Characteristics Of Moderate-To-Severe Thyroid Associated Ophthalmopathy In 354 Chinese Cases

The significance of ophthalmological features in diagnosis of thyroid-associated ophthalmopathy

A Comparison of the Clinical Efficacy on Treatment of Thyroid Associated Ophthalmopathy with Periocular Triamcinolone and High-Dose Oral Prednisone

Thyroid-associated ophthalmopathy: cu-rrent concepts regarding etiopathogenesis and management

Thyroid-Associated Ophthalmopathy: Preliminary Study Using T2 Mapping to Characterize Intraorbital Optic Nerve Changes Before Dysthyroid Optic Neuropathy.

Current Status and Research Progress in the Conservative Treatment of Thyroid -Associated Ophthalmopathy

Ocular Surface Damage and Correlative Factors in Thyroid Associated Ophthalmopathy

[Thyroid orbitopathy and diabetes]

Effect of high-dose glucocorticoid on adrenal cortex in treatment of thyroid associated ophthalmopathy

Clinical Characteristics of Patients with Euthyroid Thyroid-associated Ophthalmopathy

Thyroid-associated Orbitopathy in Patients with Thyroid Carcinoma A Case Report of 5 Cases

Concomitant Idiopathic Orbital Inflammatory Pseudotumor and Thyroid-Associated Ophthalmopathy

Perioperative nursing about 10 patients who have accepted decompression of orbit to cure thyroid-associated ophthalmopathy

Study Progress of High Dose Intravenous Glucocorticoid Pulse Therapy in the Treatment of Thyroid-associated Ophthalmopathy